Sonova (OTCMKTS:SONVY) Stock Rating Upgraded by BNP Paribas Exane

Sonova (OTCMKTS:SONVY) was upgraded by research analysts at BNP Paribas Exane from a “strong sell” rating to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

A number of other research analysts have also weighed in on the company. Royal Bank Of Canada raised Sonova to a “moderate buy” rating in a research note on Tuesday, November 18th. Zacks Research raised Sonova from a “strong sell” rating to a “hold” rating in a research report on Monday, February 9th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.

Sonova Stock Performance

Shares of SONVY opened at $49.75 on Tuesday. Sonova has a 1 year low of $47.55 and a 1 year high of $68.76. The company’s 50 day simple moving average is $52.79 and its 200 day simple moving average is $53.75. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.24 and a quick ratio of 0.91.

About Sonova

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.